advertisement
Abstract #20119 Published in IGR 9-4
Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma
Kumar RS; Istiantoro VW; Hoh S-T; Ho C-L; Oen FT; Aung TJournal of Glaucoma 2007; 16: 606-609
PURPOSE: To assess the efficacy and safety of systematically switching a large number of hospital-based glaucoma patients from latanoprost to travoprost therapy. MATERIALS AND METHODS: In this prospective observational study, patients on latanoprost were systematically switched to travoprost without washout and followed-up for 12 weeks. The main outcome measures were control of intraocular pressure (IOP), rate of switching back, and tolerability. IOP was measured at baseline (while on latanoprost), and at weeks six and 12 after switching to travoprost. Adverse effects were assessed and conjunctival hyperemia was graded using a standardized scale. RESULTS: Ninety-three consecutive patients (mean age 63.3± 12.1 y) were enrolled. Nine patients were lost to follow-up. Four patients (4.3%) were switched back to latanoprost after six weeks due to travoprost intolerance. There was no significant difference between mean IOP at baseline (16.4 ± 3.4 mmHg, 95% confidence interval [CI] 15.6-17.2) and that at week six (15.9 ± 4.2 mmHg, 95% CI 14.9-16.8) (P = 0.2) and week 12 (16.4 ± 5.7 mmHg, 95% CI 15.1-17.7) (P = 0.99). There was no significant difference in the mean hyperemia score at week 12 compared with baseline (P = 0.09). The majority of patients (86.9%) felt that both medications were comparable in terms of degree of comfort; five felt that travoprost caused more redness. CONCLUSIONS: In this study, when glaucoma patients were systematically switched from latanoprost to travoprost, the efficacy and safety of the two medications were found to be comparable. A high switch rate (95.2%) was achieved with average hyperemia scores being comparable.
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
